Cell Death & Disease-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2172298, encodeId=9a6d21e22984c, content=有大佬知道系统上出现 This manuscript has already been approved. Thank you.是什么意思吗，状态还是under consideration ，投了28天了，昨天写了一封催稿信, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ9fWIeibNYic76ibSvVO7ibGnBxl3RuJ3XoPQ9icVxc5neKh7e8tBzPyKF75Depicw4xdvZsWtsnt3W1JA/132, createdBy=d08f5307880, createdName=南风, createdTime=Fri Dec 01 12:03:44 CST 2023, time=2023-12-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2171414, encodeId=0d6921e14142b, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9.28接收到的正式接收邮件 10.12支付的稿费 到现在一直没有online，大家有遇到这种吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Tue Nov 28 10:05:57 CST 2023, time=2023-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2158299, encodeId=f66c215829949, content=偏重的研究方向：肿瘤;细胞死亡 经验分享：今年投了两篇，第一篇26天送审，84天一审完，修回后7天接收。第二篇16天送审，目前还在审。给审稿人的时间是14天，时间一般就是耽误在编辑找审稿人阶段，还有版面费33000不是一般的贵，真实接受率在25%多左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Mon Sep 18 15:30:18 CST 2023, time=2023-09-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169821, encodeId=c11021698215f, content=想问问大家出现zip for reviewer 代表外审吗状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Mon Nov 20 20:35:33 CST 2023, time=2023-11-20, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153958, encodeId=82362153958ff, content=原则性接收后多久正式接收啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/20/a60a5439109ead7366f1f4971bdbe345.jpg, createdBy=73672189015, createdName=巍巍123, createdTime=Mon Aug 21 22:50:38 CST 2023, time=2023-08-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170123, encodeId=187121e012348, content=我已经112天了，一审还没回，等的好着急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f08601112, createdName=ms3000000126427156, createdTime=Wed Nov 22 08:14:22 CST 2023, time=2023-11-22, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159351, encodeId=f82021593514a, content=偏重的研究方向：乳腺癌;肿瘤;细胞生物学 经验分享：我有两个通讯作者，以主通讯的账号提交的，原则性接收之后提出两个通讯作者都要提供ORCID号，可是提交系统里没法选择添加通讯作者也没有办法添加另一个通讯作者的ORCID号。请问有人遇到过这个问题吗？怎么解决呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f37c8859134, createdName=ms8000000581086158, createdTime=Sat Sep 23 22:31:30 CST 2023, time=2023-09-23, status=1, ipAttribution=广东省)]

2023-08-25 1245a556m23暂无昵称来自河南省

从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？

52 16

展开16条回复

[GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2172298, encodeId=9a6d21e22984c, content=有大佬知道系统上出现 This manuscript has already been approved. Thank you.是什么意思吗，状态还是under consideration ，投了28天了，昨天写了一封催稿信, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ9fWIeibNYic76ibSvVO7ibGnBxl3RuJ3XoPQ9icVxc5neKh7e8tBzPyKF75Depicw4xdvZsWtsnt3W1JA/132, createdBy=d08f5307880, createdName=南风, createdTime=Fri Dec 01 12:03:44 CST 2023, time=2023-12-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2171414, encodeId=0d6921e14142b, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9.28接收到的正式接收邮件 10.12支付的稿费 到现在一直没有online，大家有遇到这种吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Tue Nov 28 10:05:57 CST 2023, time=2023-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2158299, encodeId=f66c215829949, content=偏重的研究方向：肿瘤;细胞死亡 经验分享：今年投了两篇，第一篇26天送审，84天一审完，修回后7天接收。第二篇16天送审，目前还在审。给审稿人的时间是14天，时间一般就是耽误在编辑找审稿人阶段，还有版面费33000不是一般的贵，真实接受率在25%多左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Mon Sep 18 15:30:18 CST 2023, time=2023-09-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169821, encodeId=c11021698215f, content=想问问大家出现zip for reviewer 代表外审吗状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Mon Nov 20 20:35:33 CST 2023, time=2023-11-20, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153958, encodeId=82362153958ff, content=原则性接收后多久正式接收啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/20/a60a5439109ead7366f1f4971bdbe345.jpg, createdBy=73672189015, createdName=巍巍123, createdTime=Mon Aug 21 22:50:38 CST 2023, time=2023-08-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170123, encodeId=187121e012348, content=我已经112天了，一审还没回，等的好着急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f08601112, createdName=ms3000000126427156, createdTime=Wed Nov 22 08:14:22 CST 2023, time=2023-11-22, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159351, encodeId=f82021593514a, content=偏重的研究方向：乳腺癌;肿瘤;细胞生物学 经验分享：我有两个通讯作者，以主通讯的账号提交的，原则性接收之后提出两个通讯作者都要提供ORCID号，可是提交系统里没法选择添加通讯作者也没有办法添加另一个通讯作者的ORCID号。请问有人遇到过这个问题吗？怎么解决呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f37c8859134, createdName=ms8000000581086158, createdTime=Sat Sep 23 22:31:30 CST 2023, time=2023-09-23, status=1, ipAttribution=广东省)]

2023-12-01 南风来自山东省

有大佬知道系统上出现 This manuscript has already been approved. Thank you.是什么意思吗，状态还是under consideration ，投了28天了，昨天写了一封催稿信

1 0

[GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2172298, encodeId=9a6d21e22984c, content=有大佬知道系统上出现 This manuscript has already been approved. Thank you.是什么意思吗，状态还是under consideration ，投了28天了，昨天写了一封催稿信, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ9fWIeibNYic76ibSvVO7ibGnBxl3RuJ3XoPQ9icVxc5neKh7e8tBzPyKF75Depicw4xdvZsWtsnt3W1JA/132, createdBy=d08f5307880, createdName=南风, createdTime=Fri Dec 01 12:03:44 CST 2023, time=2023-12-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2171414, encodeId=0d6921e14142b, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9.28接收到的正式接收邮件 10.12支付的稿费 到现在一直没有online，大家有遇到这种吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Tue Nov 28 10:05:57 CST 2023, time=2023-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2158299, encodeId=f66c215829949, content=偏重的研究方向：肿瘤;细胞死亡 经验分享：今年投了两篇，第一篇26天送审，84天一审完，修回后7天接收。第二篇16天送审，目前还在审。给审稿人的时间是14天，时间一般就是耽误在编辑找审稿人阶段，还有版面费33000不是一般的贵，真实接受率在25%多左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Mon Sep 18 15:30:18 CST 2023, time=2023-09-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169821, encodeId=c11021698215f, content=想问问大家出现zip for reviewer 代表外审吗状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Mon Nov 20 20:35:33 CST 2023, time=2023-11-20, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153958, encodeId=82362153958ff, content=原则性接收后多久正式接收啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/20/a60a5439109ead7366f1f4971bdbe345.jpg, createdBy=73672189015, createdName=巍巍123, createdTime=Mon Aug 21 22:50:38 CST 2023, time=2023-08-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170123, encodeId=187121e012348, content=我已经112天了，一审还没回，等的好着急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f08601112, createdName=ms3000000126427156, createdTime=Wed Nov 22 08:14:22 CST 2023, time=2023-11-22, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159351, encodeId=f82021593514a, content=偏重的研究方向：乳腺癌;肿瘤;细胞生物学 经验分享：我有两个通讯作者，以主通讯的账号提交的，原则性接收之后提出两个通讯作者都要提供ORCID号，可是提交系统里没法选择添加通讯作者也没有办法添加另一个通讯作者的ORCID号。请问有人遇到过这个问题吗？怎么解决呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f37c8859134, createdName=ms8000000581086158, createdTime=Sat Sep 23 22:31:30 CST 2023, time=2023-09-23, status=1, ipAttribution=广东省)]

2023-05-18 36192448 来自湖南省

偏重的研究方向：细胞死亡
经验分享：一审65天了，还没消息，彻底躺平了

52 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2172298, encodeId=9a6d21e22984c, content=有大佬知道系统上出现 This manuscript has already been approved. Thank you.是什么意思吗，状态还是under consideration ，投了28天了，昨天写了一封催稿信, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ9fWIeibNYic76ibSvVO7ibGnBxl3RuJ3XoPQ9icVxc5neKh7e8tBzPyKF75Depicw4xdvZsWtsnt3W1JA/132, createdBy=d08f5307880, createdName=南风, createdTime=Fri Dec 01 12:03:44 CST 2023, time=2023-12-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2171414, encodeId=0d6921e14142b, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9.28接收到的正式接收邮件 10.12支付的稿费 到现在一直没有online，大家有遇到这种吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Tue Nov 28 10:05:57 CST 2023, time=2023-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2158299, encodeId=f66c215829949, content=偏重的研究方向：肿瘤;细胞死亡 经验分享：今年投了两篇，第一篇26天送审，84天一审完，修回后7天接收。第二篇16天送审，目前还在审。给审稿人的时间是14天，时间一般就是耽误在编辑找审稿人阶段，还有版面费33000不是一般的贵，真实接受率在25%多左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Mon Sep 18 15:30:18 CST 2023, time=2023-09-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169821, encodeId=c11021698215f, content=想问问大家出现zip for reviewer 代表外审吗状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Mon Nov 20 20:35:33 CST 2023, time=2023-11-20, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153958, encodeId=82362153958ff, content=原则性接收后多久正式接收啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/20/a60a5439109ead7366f1f4971bdbe345.jpg, createdBy=73672189015, createdName=巍巍123, createdTime=Mon Aug 21 22:50:38 CST 2023, time=2023-08-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170123, encodeId=187121e012348, content=我已经112天了，一审还没回，等的好着急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f08601112, createdName=ms3000000126427156, createdTime=Wed Nov 22 08:14:22 CST 2023, time=2023-11-22, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159351, encodeId=f82021593514a, content=偏重的研究方向：乳腺癌;肿瘤;细胞生物学 经验分享：我有两个通讯作者，以主通讯的账号提交的，原则性接收之后提出两个通讯作者都要提供ORCID号，可是提交系统里没法选择添加通讯作者也没有办法添加另一个通讯作者的ORCID号。请问有人遇到过这个问题吗？怎么解决呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f37c8859134, createdName=ms8000000581086158, createdTime=Sat Sep 23 22:31:30 CST 2023, time=2023-09-23, status=1, ipAttribution=广东省)]

2023-11-28 ms6000001686001327 来自上海

审稿速度:12.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：9.28接收到的正式接收邮件
10.12支付的稿费
到现在一直没有online，大家有遇到这种吗

6 0

[GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2172298, encodeId=9a6d21e22984c, content=有大佬知道系统上出现 This manuscript has already been approved. Thank you.是什么意思吗，状态还是under consideration ，投了28天了，昨天写了一封催稿信, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ9fWIeibNYic76ibSvVO7ibGnBxl3RuJ3XoPQ9icVxc5neKh7e8tBzPyKF75Depicw4xdvZsWtsnt3W1JA/132, createdBy=d08f5307880, createdName=南风, createdTime=Fri Dec 01 12:03:44 CST 2023, time=2023-12-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2171414, encodeId=0d6921e14142b, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9.28接收到的正式接收邮件 10.12支付的稿费 到现在一直没有online，大家有遇到这种吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Tue Nov 28 10:05:57 CST 2023, time=2023-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2158299, encodeId=f66c215829949, content=偏重的研究方向：肿瘤;细胞死亡 经验分享：今年投了两篇，第一篇26天送审，84天一审完，修回后7天接收。第二篇16天送审，目前还在审。给审稿人的时间是14天，时间一般就是耽误在编辑找审稿人阶段，还有版面费33000不是一般的贵，真实接受率在25%多左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Mon Sep 18 15:30:18 CST 2023, time=2023-09-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169821, encodeId=c11021698215f, content=想问问大家出现zip for reviewer 代表外审吗状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Mon Nov 20 20:35:33 CST 2023, time=2023-11-20, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153958, encodeId=82362153958ff, content=原则性接收后多久正式接收啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/20/a60a5439109ead7366f1f4971bdbe345.jpg, createdBy=73672189015, createdName=巍巍123, createdTime=Mon Aug 21 22:50:38 CST 2023, time=2023-08-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170123, encodeId=187121e012348, content=我已经112天了，一审还没回，等的好着急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f08601112, createdName=ms3000000126427156, createdTime=Wed Nov 22 08:14:22 CST 2023, time=2023-11-22, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159351, encodeId=f82021593514a, content=偏重的研究方向：乳腺癌;肿瘤;细胞生物学 经验分享：我有两个通讯作者，以主通讯的账号提交的，原则性接收之后提出两个通讯作者都要提供ORCID号，可是提交系统里没法选择添加通讯作者也没有办法添加另一个通讯作者的ORCID号。请问有人遇到过这个问题吗？怎么解决呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f37c8859134, createdName=ms8000000581086158, createdTime=Sat Sep 23 22:31:30 CST 2023, time=2023-09-23, status=1, ipAttribution=广东省)]

2023-09-18 36192448 来自湖南省

偏重的研究方向：肿瘤;细胞死亡
经验分享：今年投了两篇，第一篇26天送审，84天一审完，修回后7天接收。第二篇16天送审，目前还在审。给审稿人的时间是14天，时间一般就是耽误在编辑找审稿人阶段，还有版面费33000不是一般的贵，真实接受率在25%多左右。

48 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2172298, encodeId=9a6d21e22984c, content=有大佬知道系统上出现 This manuscript has already been approved. Thank you.是什么意思吗，状态还是under consideration ，投了28天了，昨天写了一封催稿信, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ9fWIeibNYic76ibSvVO7ibGnBxl3RuJ3XoPQ9icVxc5neKh7e8tBzPyKF75Depicw4xdvZsWtsnt3W1JA/132, createdBy=d08f5307880, createdName=南风, createdTime=Fri Dec 01 12:03:44 CST 2023, time=2023-12-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2171414, encodeId=0d6921e14142b, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9.28接收到的正式接收邮件 10.12支付的稿费 到现在一直没有online，大家有遇到这种吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Tue Nov 28 10:05:57 CST 2023, time=2023-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2158299, encodeId=f66c215829949, content=偏重的研究方向：肿瘤;细胞死亡 经验分享：今年投了两篇，第一篇26天送审，84天一审完，修回后7天接收。第二篇16天送审，目前还在审。给审稿人的时间是14天，时间一般就是耽误在编辑找审稿人阶段，还有版面费33000不是一般的贵，真实接受率在25%多左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Mon Sep 18 15:30:18 CST 2023, time=2023-09-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169821, encodeId=c11021698215f, content=想问问大家出现zip for reviewer 代表外审吗状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Mon Nov 20 20:35:33 CST 2023, time=2023-11-20, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153958, encodeId=82362153958ff, content=原则性接收后多久正式接收啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/20/a60a5439109ead7366f1f4971bdbe345.jpg, createdBy=73672189015, createdName=巍巍123, createdTime=Mon Aug 21 22:50:38 CST 2023, time=2023-08-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170123, encodeId=187121e012348, content=我已经112天了，一审还没回，等的好着急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f08601112, createdName=ms3000000126427156, createdTime=Wed Nov 22 08:14:22 CST 2023, time=2023-11-22, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159351, encodeId=f82021593514a, content=偏重的研究方向：乳腺癌;肿瘤;细胞生物学 经验分享：我有两个通讯作者，以主通讯的账号提交的，原则性接收之后提出两个通讯作者都要提供ORCID号，可是提交系统里没法选择添加通讯作者也没有办法添加另一个通讯作者的ORCID号。请问有人遇到过这个问题吗？怎么解决呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f37c8859134, createdName=ms8000000581086158, createdTime=Sat Sep 23 22:31:30 CST 2023, time=2023-09-23, status=1, ipAttribution=广东省)]

2023-11-20 123a6632m26暂无昵称来自辽宁省

想问问大家出现zip for reviewer 代表外审吗状态还是under consideration

7 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2172298, encodeId=9a6d21e22984c, content=有大佬知道系统上出现 This manuscript has already been approved. Thank you.是什么意思吗，状态还是under consideration ，投了28天了，昨天写了一封催稿信, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ9fWIeibNYic76ibSvVO7ibGnBxl3RuJ3XoPQ9icVxc5neKh7e8tBzPyKF75Depicw4xdvZsWtsnt3W1JA/132, createdBy=d08f5307880, createdName=南风, createdTime=Fri Dec 01 12:03:44 CST 2023, time=2023-12-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2171414, encodeId=0d6921e14142b, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9.28接收到的正式接收邮件 10.12支付的稿费 到现在一直没有online，大家有遇到这种吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Tue Nov 28 10:05:57 CST 2023, time=2023-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2158299, encodeId=f66c215829949, content=偏重的研究方向：肿瘤;细胞死亡 经验分享：今年投了两篇，第一篇26天送审，84天一审完，修回后7天接收。第二篇16天送审，目前还在审。给审稿人的时间是14天，时间一般就是耽误在编辑找审稿人阶段，还有版面费33000不是一般的贵，真实接受率在25%多左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Mon Sep 18 15:30:18 CST 2023, time=2023-09-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169821, encodeId=c11021698215f, content=想问问大家出现zip for reviewer 代表外审吗状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Mon Nov 20 20:35:33 CST 2023, time=2023-11-20, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153958, encodeId=82362153958ff, content=原则性接收后多久正式接收啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/20/a60a5439109ead7366f1f4971bdbe345.jpg, createdBy=73672189015, createdName=巍巍123, createdTime=Mon Aug 21 22:50:38 CST 2023, time=2023-08-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170123, encodeId=187121e012348, content=我已经112天了，一审还没回，等的好着急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f08601112, createdName=ms3000000126427156, createdTime=Wed Nov 22 08:14:22 CST 2023, time=2023-11-22, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159351, encodeId=f82021593514a, content=偏重的研究方向：乳腺癌;肿瘤;细胞生物学 经验分享：我有两个通讯作者，以主通讯的账号提交的，原则性接收之后提出两个通讯作者都要提供ORCID号，可是提交系统里没法选择添加通讯作者也没有办法添加另一个通讯作者的ORCID号。请问有人遇到过这个问题吗？怎么解决呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f37c8859134, createdName=ms8000000581086158, createdTime=Sat Sep 23 22:31:30 CST 2023, time=2023-09-23, status=1, ipAttribution=广东省)]

2023-08-21 巍巍123 来自上海

原则性接收后多久正式接收啊

35 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2172298, encodeId=9a6d21e22984c, content=有大佬知道系统上出现 This manuscript has already been approved. Thank you.是什么意思吗，状态还是under consideration ，投了28天了，昨天写了一封催稿信, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ9fWIeibNYic76ibSvVO7ibGnBxl3RuJ3XoPQ9icVxc5neKh7e8tBzPyKF75Depicw4xdvZsWtsnt3W1JA/132, createdBy=d08f5307880, createdName=南风, createdTime=Fri Dec 01 12:03:44 CST 2023, time=2023-12-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2171414, encodeId=0d6921e14142b, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9.28接收到的正式接收邮件 10.12支付的稿费 到现在一直没有online，大家有遇到这种吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Tue Nov 28 10:05:57 CST 2023, time=2023-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2158299, encodeId=f66c215829949, content=偏重的研究方向：肿瘤;细胞死亡 经验分享：今年投了两篇，第一篇26天送审，84天一审完，修回后7天接收。第二篇16天送审，目前还在审。给审稿人的时间是14天，时间一般就是耽误在编辑找审稿人阶段，还有版面费33000不是一般的贵，真实接受率在25%多左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Mon Sep 18 15:30:18 CST 2023, time=2023-09-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169821, encodeId=c11021698215f, content=想问问大家出现zip for reviewer 代表外审吗状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Mon Nov 20 20:35:33 CST 2023, time=2023-11-20, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153958, encodeId=82362153958ff, content=原则性接收后多久正式接收啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/20/a60a5439109ead7366f1f4971bdbe345.jpg, createdBy=73672189015, createdName=巍巍123, createdTime=Mon Aug 21 22:50:38 CST 2023, time=2023-08-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170123, encodeId=187121e012348, content=我已经112天了，一审还没回，等的好着急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f08601112, createdName=ms3000000126427156, createdTime=Wed Nov 22 08:14:22 CST 2023, time=2023-11-22, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159351, encodeId=f82021593514a, content=偏重的研究方向：乳腺癌;肿瘤;细胞生物学 经验分享：我有两个通讯作者，以主通讯的账号提交的，原则性接收之后提出两个通讯作者都要提供ORCID号，可是提交系统里没法选择添加通讯作者也没有办法添加另一个通讯作者的ORCID号。请问有人遇到过这个问题吗？怎么解决呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f37c8859134, createdName=ms8000000581086158, createdTime=Sat Sep 23 22:31:30 CST 2023, time=2023-09-23, status=1, ipAttribution=广东省)]

2023-11-22 ms3000000126427156 来自湖南省

我已经112天了，一审还没回，等的好着急啊

9 0

[GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2172298, encodeId=9a6d21e22984c, content=有大佬知道系统上出现 This manuscript has already been approved. Thank you.是什么意思吗，状态还是under consideration ，投了28天了，昨天写了一封催稿信, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ9fWIeibNYic76ibSvVO7ibGnBxl3RuJ3XoPQ9icVxc5neKh7e8tBzPyKF75Depicw4xdvZsWtsnt3W1JA/132, createdBy=d08f5307880, createdName=南风, createdTime=Fri Dec 01 12:03:44 CST 2023, time=2023-12-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2171414, encodeId=0d6921e14142b, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9.28接收到的正式接收邮件 10.12支付的稿费 到现在一直没有online，大家有遇到这种吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Tue Nov 28 10:05:57 CST 2023, time=2023-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2158299, encodeId=f66c215829949, content=偏重的研究方向：肿瘤;细胞死亡 经验分享：今年投了两篇，第一篇26天送审，84天一审完，修回后7天接收。第二篇16天送审，目前还在审。给审稿人的时间是14天，时间一般就是耽误在编辑找审稿人阶段，还有版面费33000不是一般的贵，真实接受率在25%多左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Mon Sep 18 15:30:18 CST 2023, time=2023-09-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169821, encodeId=c11021698215f, content=想问问大家出现zip for reviewer 代表外审吗状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Mon Nov 20 20:35:33 CST 2023, time=2023-11-20, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153958, encodeId=82362153958ff, content=原则性接收后多久正式接收啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/20/a60a5439109ead7366f1f4971bdbe345.jpg, createdBy=73672189015, createdName=巍巍123, createdTime=Mon Aug 21 22:50:38 CST 2023, time=2023-08-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170123, encodeId=187121e012348, content=我已经112天了，一审还没回，等的好着急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f08601112, createdName=ms3000000126427156, createdTime=Wed Nov 22 08:14:22 CST 2023, time=2023-11-22, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159351, encodeId=f82021593514a, content=偏重的研究方向：乳腺癌;肿瘤;细胞生物学 经验分享：我有两个通讯作者，以主通讯的账号提交的，原则性接收之后提出两个通讯作者都要提供ORCID号，可是提交系统里没法选择添加通讯作者也没有办法添加另一个通讯作者的ORCID号。请问有人遇到过这个问题吗？怎么解决呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f37c8859134, createdName=ms8000000581086158, createdTime=Sat Sep 23 22:31:30 CST 2023, time=2023-09-23, status=1, ipAttribution=广东省)]

2022-07-12 ms9000001463682571

4月12投稿
4月13检查格式通过
4月20指定责编
4月23送外审
4月25有审稿人同意审稿
5月4号审稿结束，开始决定意见
5月16日发邮件告知修回意见
7月7日修回
7月8日核对格式
7月9日决定意见
7月11日原则性接收，核对格式
7月12日正式接收

163 19

展开19条回复

[GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2172298, encodeId=9a6d21e22984c, content=有大佬知道系统上出现 This manuscript has already been approved. Thank you.是什么意思吗，状态还是under consideration ，投了28天了，昨天写了一封催稿信, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ9fWIeibNYic76ibSvVO7ibGnBxl3RuJ3XoPQ9icVxc5neKh7e8tBzPyKF75Depicw4xdvZsWtsnt3W1JA/132, createdBy=d08f5307880, createdName=南风, createdTime=Fri Dec 01 12:03:44 CST 2023, time=2023-12-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2171414, encodeId=0d6921e14142b, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：9.28接收到的正式接收邮件 10.12支付的稿费 到现在一直没有online，大家有遇到这种吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Tue Nov 28 10:05:57 CST 2023, time=2023-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2158299, encodeId=f66c215829949, content=偏重的研究方向：肿瘤;细胞死亡 经验分享：今年投了两篇，第一篇26天送审，84天一审完，修回后7天接收。第二篇16天送审，目前还在审。给审稿人的时间是14天，时间一般就是耽误在编辑找审稿人阶段，还有版面费33000不是一般的贵，真实接受率在25%多左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Mon Sep 18 15:30:18 CST 2023, time=2023-09-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169821, encodeId=c11021698215f, content=想问问大家出现zip for reviewer 代表外审吗状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Mon Nov 20 20:35:33 CST 2023, time=2023-11-20, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153958, encodeId=82362153958ff, content=原则性接收后多久正式接收啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/20/a60a5439109ead7366f1f4971bdbe345.jpg, createdBy=73672189015, createdName=巍巍123, createdTime=Mon Aug 21 22:50:38 CST 2023, time=2023-08-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2170123, encodeId=187121e012348, content=我已经112天了，一审还没回，等的好着急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f08601112, createdName=ms3000000126427156, createdTime=Wed Nov 22 08:14:22 CST 2023, time=2023-11-22, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159351, encodeId=f82021593514a, content=偏重的研究方向：乳腺癌;肿瘤;细胞生物学 经验分享：我有两个通讯作者，以主通讯的账号提交的，原则性接收之后提出两个通讯作者都要提供ORCID号，可是提交系统里没法选择添加通讯作者也没有办法添加另一个通讯作者的ORCID号。请问有人遇到过这个问题吗？怎么解决呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f37c8859134, createdName=ms8000000581086158, createdTime=Sat Sep 23 22:31:30 CST 2023, time=2023-09-23, status=1, ipAttribution=广东省)]

2023-09-23 ms8000000581086158 来自广东省

偏重的研究方向：乳腺癌;肿瘤;细胞生物学
经验分享：我有两个通讯作者，以主通讯的账号提交的，原则性接收之后提出两个通讯作者都要提供ORCID号，可是提交系统里没法选择添加通讯作者也没有办法添加另一个通讯作者的ORCID号。请问有人遇到过这个问题吗？怎么解决呢？

25 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

平台业务解决方案

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务